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Abstract
Background: Identifying the functional importance of the millions of single nucleotide polymorphisms (SNPs) in
the human genome is a difficult challenge. Therefore, a reverse strategy, which identifies functionally important
SNPs by virtue of the bimodal abundance across the human population of the SNP-related mRNAs will be useful.
Those mRNA transcripts that are expressed at two distinct abundances in proportion to SNP allele frequency may
warrant further study. Matrix metalloproteinase 1 (MMP1) is important in both normal development and in
numerous pathologies. Although much research has been conducted to investigate the expression of MMP1 in
many different cell types and conditions, the regulation of its expression is still not fully understood.
Results: In this study, we used a novel but straightforward method based on agglomerative hierarchical clustering
to identify bimodally expressed transcripts in human umbilical vein endothelial cell (HUVEC) microarray data from
15 individuals. We found that MMP1 mRNA abundance was bimodally distributed in un-treated HUVECs and
showed a bimodal response to inflammatory mediator treatment. RT-PCR and MMP1 activity assays confirmed the
bimodal regulation and DNA sequencing of 69 individuals identified an MMP1 gene promoter polymorphism that
segregated precisely with the MMP1 bimodal expression. Chromatin immunoprecipation (ChIP) experiments
indicated that the transcription factors (TFs) ETS1, ETS2 and GATA3, bind to the MMP1 promoter in the region of
this polymorphism and may contribute to the bimodal expression.
Conclusions: We describe a simple method to identify putative bimodally expressed RNAs from transcriptome
data that is effective yet easy for non-statisticans to understand and use. This method identified bimodal
endothelial cell expression of MMP1, which appears to be biologically significant with implications for inflammatory
disease. (271 Words).
Background
Numerous strategies have been used in an attempt to
sift through the vast amounts of data produced from
microarray expression studies [1-4]. There has been
much interest given to the identification of bimodally
expressed mRNA transcripts, particularly in the context
of cancer, where two distinct populations of patients
can be defined by differing levels of a set of specific
transcripts. These make excellent candidate biomarkers
and often tend to show good correlation between tran-
script and protein abundance [5]. To this end, statistical
approaches using mixture-model based clustering com-
bined with either Akaike information criterion (AIC) or
the Bayesian informatics criterion (BIC) have frequently
been applied [6-9]. One method based on systematic
classification of gene expression profiles has been
applied to over 2,000 microarray samples [10]. These
methods have a strong theoretical base and have proven
successful in identifying bimodality. However, they do
depend on the investigator having a relatively high level
of statistical understanding [7]. In this study we suggest
a simple screening approach based on hierarchical clus-
tering to identify bimodally expressed transcripts from
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more complex approaches. While this method is not
motivated by statistical theory, it appears to work well
and is easily understood by laboratory scientists with
only basic statistical training, who are in a good position
to immediately follow up their results experimentally.
The matrix metalloproteinase, MMP1, is one of the
most abundant proteases in the matrix metalloprotei-
nase family. It is capable of degrading type I, II and III
collagens, and is one of only four MMPs able to degrade
triple helical collagens. It therefore plays a pivotal role
in extracellular matrix (ECM) remodelling in both
normal development and pathology [11]. MMP1 is
tightly regulated at both the transcriptional and post-
translational levels. It is produced as a zymogen that is
activated by serine proteases and its activity is regulated
by inhibitors such as the tissue inhibitors of metallopro-
teinase’s (TIMPs), which compete with the substrate for
the enzyme active site [12].
MMP1 plays a clinically important role in inflamma-
tory disease, and has been implicated in numerous
pathological processes including wound healing [13],
tumour metastasis [14] and arthritis [15]. The MMP-1
gene [11] contains a 1G/2G polymorphism in its promo-
ter at -1607 from the transcriptional start site [16]. This
polymorphism has been associated with increased
MMP-1 expression in several cell types including; mela-
noma, stromal fibroblast, MCF-7/ADR breast cancer
cells [16-19], and with several pathologies including:
tumour metastasis [20,21], arthritis [22,23], periodontitis
[24], chronic obstructive pulmonary disease [25] and
cardiovascular disease [26,27].
Using our simple clustering method to examine RNA
transcript abundance in HUVECs isolated from 15 dif-
ferent human individuals, we identified MMP1 as one of
a small group of RNAs expressed in a bimodal manner
in both un-treated endothelial cells, and in endothelial
cells treated by inflammatory mediators. Our results
suggest that the regulation of MMP1 expression is a
complex process that is modulated by a promoter poly-
morphism around the binding sites for several TFs
including ETS1, ETS2 and GATA3.
Results
Identification of mRNA transcripts with bimodal
expression patterns among a set of individuals
Bimodally or multimodally expressed mRNA transcripts
were defined as those transcripts for which two or more
distinct populations of expression values were observed
among a set of individuals. To identify and visualise
bimodally expressed transcripts, we devised a simple
algorithm (written as a script in the statistical language
‘R’; Additional File 1) based on unsupervised agglomera-
tive hierarchical clustering. The algorithm can be used
as either a simple ‘R’ script, or for use in graphical user
interface it can be supplied as a GenePattern module on
request (http://www.broadinstitute.org/cancer/software/
genepattern/). It is illustrated schematically in Figure 1
and described in the methods section. Briefly, on a tran-
script-by-transcript basis, agglomerative hierarchical
clustering across the dataset was carried out. The maxi-
mum cluster branch height identified for each transcript
was approximately proportional to the greatest distance
between the any two clusters of individuals, and is used
here a surrogate marker for the degree of bimodal
expression. To estimate the probability of transcripts
appearing to be bimodally expressed due to chance
alone we used a parametric bootstrapping method.
Related methods where trees are constructed from re-
sampled data have been used previously to assess the
reliability of clusters in gene expression data [28]. As is
often the case with microarray transcript abundance
data, our log-transformed data approximated a normal
distribution. Therefore, for each transcript we made a
maximum likelihood estimate of the parameters of a
normally distributed population from which the sample
of individuals being studied may have been drawn.
These parameters (mean and standard deviation) were
then used to generate 10,000 simulated datasets for the
transcript, each of which was clustered as described
above. From the 10,000 clustering results we identified
how frequently the largest distance between clusters ≥
the largest distance between clusters in the actual data
set. This information is used generate an empirical
p-value as an estimate of type I error rate.
This algorithm was applied to two RNA microarray data
sets: (i) data from HUVECs from 15 different human
individuals cultured to passage 4 in standard conditions
(the untreated data set; UT) and (ii) data from passage 4
HUVECs from nine different human individuals cul-
tured with a cocktail of 10 ng/ml TNF-a,I L - 1 b and
IL-8 for 24 hours (the IM-treated data set; IM). The
bimodally expressed RNAs found in the UT and IM
HUVECs are listed in Additional File 2. The relationship
between the maximum branch height (an estimate of
the degree of bimodal expression) and the -log2 trans-
formed empirical p-value (an estimate of the frequency
of a transcript appearing to be bimodally expressed due
to chance alone) is shown in Figure 2A-B. In each of
the un-treated and IM-treated data sets, a relatively
small group of transcripts with high maximum branch
height and high -log2 p were identified. We decided to
accept an estimated type I error rate of 10% for each
of these data sets, and found there were 21 RNA tran-
scripts for which the empirical p-values were ≤ 0.1 in
both the un-treated and IM-treated data sets
(Figure 2C). A table of features for each of the 21 short-
listed RNA transcripts is given in Additional file 3.
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Page 2 of 13These shortlisted transcripts were further assessed using
several strategies including; i) visual inspection of histo-
grams on a gene by gene basis (an R script used to gen-
erate these is given in Additional File 4); ii) evaluation
of the associated bootstrap p-values obtained during
clustering and iii) consideration of additional informa-
tion of biomedical interest. We were especially inter-
ested in the presence of promoter SNPs, which may in
theory cause bimodal RNA expression patterns, for
example using the SNPer [29] or rSNPs [30] databases.
Based on all these considerations, subset of transcripts
were selected to take forward for further investigation;
DDX3Y (a Y-chromosome encoded RNA, which should
segregate with gender), MMP1 and SLC2A11 (biologi-
cally interesting TNFa and IFNg targets, which are
important in inflammation).
(A) Generate Expression Data (B) Agglomerative Clustering of RNA xn
across several individuals 
Clustering Dendrogram
Identify largest 
distance between 
clusters (excluding
clusters of 1 individual)
Expression of RNAs x1 …x n
in several individuals
(D) Estimate type I error rate (C) Parametric Bootstrapping for RNA xn
Agglomerative Clustering of RNA xn in each of 
10,000 simulated datasets that have parameters modelled on
the population from which the n individuals were drawn 
Identify how often (largest distance between clusters) 
in the 10,000 bootstrapped data sets 싩 (largest distance 
between clusters) in the actual data set
Figure 1 Flow diagram of method to identify bimodally expressed transcripts from expression data. (A) Transcript abundance is
quantified by microarray or RNAseq techniques. (B) On a transcript-by-transcript basis, agglomerative clustering across the dataset is carried out.
The algorithm starts by assigning the same number of clusters as individuals (in this example 10 clusters were assigned since there are 10
individuals). The clusters are then progressively merged by combining the two most similar clusters, using Wards method to calculate the
distance between clusters and Euclidian distance to calculate dissimilarities between the individuals. The distances between the merging clusters
are recorded by the algorithm as branch “heights”. The height values at either side of the dendrogram are removed to exclude transcripts that
falsely appear to be bimodally expressed due to a single outlying individual. The maximum remaining branch height value (indicated by the red
arrow) is identified for each transcript, which represents the greatest distance between the any two clusters of individuals, and is used a
surrogate marker for the degree of bimodal expression for that particular transcript. (C) To estimate the probability of transcripts appearing to be
bimodally expressed due to chance alone, for each transcript we make a maximum likelihood estimate of the parameters of the distribution of
this transcript’s abundance across the population from which the individuals being studied have been drawn. We use these parameters to
generate 10,000 simulated datasets, each of which is clustered as described in (B) above. (D) In the 10,000 clusters formed from the
bootstrapped data sets for this transcript, we identify how commonly the largest distance between clusters ≥ the largest distance between
clusters in the actual data set. This information is shown graphically and is used generate an empirical p-value as an estimate of type I error rate.
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Page 3 of 13DDX3Y is differentially expressed on the basis of its
location on the Y-chromosome
The pool of individuals examined was expanded and the
abundance of DDX3Y, MMP1 and SLC2A11 mRNA in
HUVECs from 29 additional individuals cultured in both UT
and IM conditions was analysed using quantitative Reverse
Transcription-PCR (qRT-PCR). We confirmed in this new
group of individuals a bimodal expression pattern for
DDX3Y using q RT-PCR. DDX3Y is encoded by a Y-chro-
mosome gene and, as expected, its expression segregated
with the gender of the individual from which the HUVEC
were isolated in both the IM and UT data (Figure 3).
MMP1 is differentially expressed and differentially active
in endothelial cells
MMP1 was of particular interest since it encodes a biologi-
cally and clinically important enzyme, and since analysis of
the rSNPs database identified several common SNPs in the
MMP1 gene promoter within 2,000 bp upstream of the
start of transcription (data not shown). Dendrograms for
MMP1 in un-treated and IM-treated HUVECs, along with
histograms of the maximum cluster branch height in each
of 10,000 parametric bootstrap data sets (to estimate the
probability of transcripts appearing to be bimodally
expressed due to chance alone) are shown in Figure 4.
Figure 2 Microarray data of approximately 16,000 transcripts in un-treated HUVECs from 15 individuals and IM-treated HUVECs from
9 individuals were analysed separately using the clustering method described in this paper. The maximum branch height (max height,
an estimate of the degree of bimodal expression) for each transcript was plotted against the -log2 empirical p-value (an estimate of the
frequency of that transcript appearing to be bimodally expressed due to chance alone) for the un-treated data set (A) and the IM-treated data
set (B). The 21 RNA transcripts for which the empirical p-values were ≤ 0.1 in both the un-treated and IM-treated data sets were identified and
are listed alphabetically in panel (C).
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Page 4 of 13Quantitative RT-PCR from 29 additional individuals con-
firmed in this new group of individuals a bimodal expres-
sion pattern for MMP1. We identified two distinct
populations; (i) HUVECs isolated from 7 of the 29 indivi-
duals had low MMP1 mRNA abundance (Figure 5a), how-
ever in 6 of these 7 individuals, MMP1 mRNA abundance
was significantly increased by culture in IM conditions
(Figure 5b). (ii) The remaining 22 individuals had relatively
higher MMP1 mRNA abundance regardless of UT or IM
culture conditions (Figure 5a). In the high MMP1 expres-
sing HUVECs isolated from these 22 individuals, the abun-
dance of MMP1 mRNA was either not significantly
affected or was decreased by IM culture conditions
(Figure 5b). This differential response to inflammatory
mediator treatment was striking and we sought to under-
stand the underlying mechanisms.
To investigate whether the bimodal expression of
MMP1 mRNA was also evident at the level of MMP1
enzymatic activity, this activity was measured in 20
HUVEC isolates. The activity of MMP1 was low in
those HUVEC cultures that had low MMP1 RNA abun-
dance and high in those HUVEC cultures that had high
MMP1 RNA abundance (Figure 5c).
MMP-1 gene promoter polymorphisms segregate with
MMP1 expression and enzymatic activity
A 1G/2G deletion/insertion polymorphism at position
-1607 in the MMP-1 promoter has been associated with
differential expression of this gene in fibroblast and mela-
noma cells, with the 2G genotype associated with higher
basal levels of MMP1 mRNA [16]. This polymorphism
occurs within a consensus binding site for the ETS family
of transcription factors [16,18]. Therefore, direct DNA
sequencing of the MMP1 promoter was carried out to
determine whether the MMP1 mRNA abundance and
activity profiles segregated with this promoter poly-
morphism. We determined MMP1 mRNA level, MMP1
enzymatic activity and MMP1 promoter genotypes in
HUVECs from 69 different individuals. Figure 6 and
Table 1 illustrate the three genotypes observed in these
individuals. Of the 69 individuals, 76% were heterozygous
at the site of the promoter polymorphism, 15% were
homozygous for the 1G allele, while only 9% were homo-
zygous for the 2G allele. All 1G homozygous individuals
segregated with low basal expression and activity of
MMP1, whereas all but one of the heterozygotes and
homozygous 2G individuals segregated with high basal
expression and activity of MMP1.
Elevated MMP1 expression induced by inflammatory
mediator in 1G homozygous cells is not due to greater
overall activity of pro-inflammatory signalling pathways
It was possible that the differential responses to IM treat-
ment we observed between individuals with low MMP1
basal expression (homozygous 1G individuals) and high
MMP1 basal expression (heterozygotes and homozygous
2G individuals) were simply due to differential activity of
the signalling pathways that mediate inflammation.
Therefore, molecules known to be downstream of inflam-
matory mediator signalling were assessed as biomarkers
of inflammatory pathway activity in individuals with low
and high MMP1 basal expression. Protein expression
levels in ICAM1, IкBa and phospho-IкBa were measured
in HUVEC lysates from three individuals with low basal
MMP1 mRNA and three with high basal MMP1 mRNA,
after treatment with 10 ng/ml IL-1b,T N F - a and IL-8 for
up to 3.5hrs. Figure 7 shows abundance of ICAM-1, total
and phospho-IкBa over the 3.5hr period. Two-way analy-
sis of variance (ANOVA) revealed that there was no sig-
nificant difference in ICAM1 or total and phospho-IкBa
signal between the high and low expressers at all time
points (P = 0.8, 0.7 and 0.2 respectively). These results
suggest that there is not a large systematic difference
between the inflammatory signalling pathways related to
this polymorphism.
Ets1, Ets2, Fos and GATA3 are potential mediators of the
different expression levels of MMP1 mRNA in 1G -vs- 2G
individuals
To determine whether differential binding of transcrip-
tion factors to the MMP1 promoter region containing
the -1607 polymorphism is a potential mechanism for
the differential response of MMP1 to IM treatment, the
TFSEARCH algorithm [31] was used to identify putative
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Figure 3 Quantitative PCR of transcripts DDX3Y and MMP1 in
29 donor isolates under untreated (UT) and inflammatory
mediator treated (IM) conditions. Donors of female gender are
shown in red and donors of male gender are shown in black. Only
DDX3Y appears to segregate with gender. Delta Ct values are
calculated as Ct of target gene of interest (DDX3Y or MMP1) relative
to the Ct value of the internal control (18S ribosomal RNA). Low delta
Ct values represent high basal levels of expression and vice versa.
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Page 5 of 13transcription factor binding sites in this region. This
analysis revealed in addition to the ETS binding domain
spanning the polymorphic region, AP-1 and GATA3
binding sites were located 44 bp and 5 bp respectively
downstream from the polymorphism. To determine
whether these TFs actually bind to this region of the
MMP1 gene promoter, immunoprecipitation using anti-
bodies against c-fos, ETS1, ETS2 and GATA3 was car-
ried out in HUVECs isolated from two individuals of 1G
genotype and in HUVECs isolated from two individuals
of 2G genotype cultured in both IM and UT conditions.
Quantitative PCR was used to measure the enrichment
of the immunoprecipitated region (157 bp region, adja-
cent to an ETS, GATA3, AP-1 and NFKB binding site),
relative to a 173 bp region positioned 5600 bases
upstream of the polymorphism that contained no rele-
vant motifs. DNA precipitated by anti-c-fos, anti-ETS1,
anti-ETS2 and anti-GATA3 antibodies was enriched for
the MMP1 promoter region containing the polymorph-
ism, relative to the control upstream region and relative
Figure 4 Dendrograms and histograms for MMP1 in untreated and IM treated HUVECS. Dendrograms of MMP1 RNA expressions are
shown for the un-treated (A) and IM-treated (C) HUVECs. Histograms showing the frequency (y-axis) of maximum branch height (x-axis) across
10,000 simulated MMP1 transcript datasets, each with parameters similar to the estimated parameters of the population from which the actual
MMP1 data set was drawn, are shown (B and D). Green arrows indicate the maximum branch height from cluster analysis of the actual data sets.
In both un-treated and IM-treated HUVECs, the maximum clustering branch height for MMP1 exceeded the maximum clustering branch height
identified in 90% of the simulated data sets.
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Page 6 of 13to the un-immunoprecipitated material in all four indivi-
duals and in cells cultured in UT and IM conditions
(Figure 8). The aim of this experiment was to identify
potential TF binding around the polymorphism, not to
compare the degree of enrichment between IG and 2G
individuals or between UT or IM cultured cells, which
was impossible due to the small study size and variable
degree of enrichment between individuals (Figure 8).
Nevertheless, it was interesting to observe that, consis-
tent with the previously published role of ETS1 in
MMP-1 induction [16], ETS1 binding was reproducibly
enriched in the 1G isolates treated with IM.
Discussion
The significance of non-coding polymorphisms in pathol-
ogy is being increasingly recognised, with much research
b.
c.
Basal Low Expresser Basal High Expresser
a.
Figure 5 Differential expression of MMP1 in un-treated and inflammatory mediator-treated HUVECs isolated from 29 separate
individuals. (a) Quantitative RT-PCR measuring MMP1 abundance in un-treated (UT) and inflammatory mediator-treated (IM) conditions
identified two distinct populations; HUVECs isolated from seven individuals had low MMP1 mRNA abundance regardless of UT or IM culture
conditions (labelled as Basal Low Expressers), while HUVECs isolated from the other 22 individuals had relatively higher MMP1 mRNA abundance
regardless of UT or IM culture conditions (labelled as Basal High Expressers) (P < 0.0001, Mann Whitney non parametric test). (b) To illustrate the
regulation of MMP1 mRNA abundance by inflammatory mediator-treatment, the fold change in MMP1 abundance in IM -vs- UT conditions is
shown. In six out of the seven Basal Low Expressers MMP1 abundance was increased in response to IM treatment. In contrast, in 19 out of the
22 Basal High Expressers MMP1 abundance either did not change significantly or fell slightly in response to IM treatment. Both the difference in
mRNA abundance between the untreated and the inflammatory mediator treated conditions and the differential response between the high
and low basal expressers to inflammatory mediator treatment showed statistical significance (Paired t-test, P < 0.0001 and Mann Whitney
nonparametric test, P = 0.002 respectively). (c) Total MMP1 enzymatic activity was measured in a subset of the HUVEC isolates. In general low
basal expressers have lower enzyme activity than high basal expressers.
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Page 7 of 13being carried out to identify the functional importance of
the millions of SNPs mapped to date in the human gen-
ome [32]. This study suggests a complementary strategy,
whereby we first identified those transcripts that showed
bimodal expression levels, and then identified the poly-
morphism responsible for this differential expression.
Clustering methods [6] and statistical methods [7,10,33]
have previously been used to identify bimodal expression
in large datasets. These methods have the advantage of
being motivated by strong theoretical statistical consid-
erations. However, they also require a moderate level of
statistical understanding, and in addition some of these
methods can only be easily applied to large-scale meta-
analysis of several data sets [10] and may be less suitable
for small expression data sets generated in a single
laboratory. The approach we suggest is able to be used
alongside more complex approaches by laboratory scien-
tists with only basic statistical training, who are in a good
position to immediately follow up their results experi-
mentally. We believe that for bioinformatic tasks such as
this, providing several complimentary methods that span
the continuum of statistical complexity is important in
order to bridge the gap between experimental biologists
and statisticians.
Our clustering strategy successfully identified the
abundance of several mRNA transcripts including
MMP1 as bimodally distributed in human endothelial
cells in both resting and inflammatory mediator-treated
conditions. Up-regulated MMP1 expression has been
associated with many pathologies in which endothelial
cells are involved [20,21,26,27]. We sequenced the
region spanning the well characterised polymorphism at
-1607 from the transcription start site in the MMP-1
promoter [16-19] and found that this polymorphism
was strongly associated with the bimodal expression
observed in the HUVEC dataset. Individuals either
homozygous or heterozygous for the 2G polymorphism
at -1607 possessed constitutively higher levels of MMP1
(over 100 fold relative to the 1G isolates, P < 0.0001),
implying a dominant effect of the 2G allele. This con-
trasts with previous findings in fibroblasts, where mar-
ginal differences in the basal levels of MMP1 between
the 1G and 2G isolates were observed [17,34].
Inflammatory mediator treatment revealed a differential
response in MMP1 stimulation between HUVEC isolates
homozygous for the 1G allele and those possessing the 2G
allele. Whereas MMP1 mRNA levels were increased in all
isolates homozygous for the 1G allele; in isolates posses-
sing the 2G allele, MMP1 mRNA levels were essentially
unchanged (Figure 5). Regulation at the level of MMP1
enzyme activity mirrored this response to inflammatory
mediator treatment. One possibility is that MMP1 expres-
sion is at maximum levels in the 2G isolates, even under
the basal condition. In leukocytes continuously treated
with high doses of inflammatory mediators (50 ng/ml, of
TNF-a and Il-1b, 2 or 3 times over 24hrs), MMP1 mRNA
levels are genotype independent [24]. Whether this is the
case in HUVECs remains to be determined.
Figure 6 Sequencing of the -1607 MMP-1 promoter polymorphism, illustrating the homozygous and heterozygous genotypes. Insertion
of an additional G creates the consensus sequence for the ETS binding site, GGA (indicated by blue shading).
Table 1 Segregation of genotype for the -1607 MMP-1
promoter polymorphism with basal abundance of MMP-1
transcript
High Basal
Expression
Low Basal
Expression
Total
Homozygous
1G SNP
01 1 11
Homozygous
2G SNP
51 6
Heterozygous
1G/2G SNP
52 0 52
Total 57 12 69
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Page 8 of 13Chromatin immunoprecipitation (ChIP) was con-
ducted to investigate the potential involvement of TFs
that have putative response elements spanning the
polymorphism. We found that three TFs bound to this
polymorphic region of the MMP1 promoter in
endothelial cells. Using nuclear extracts from fibro-
blast and A2058 melanoma cells, Rutter et al. pre-
viously demonstrated that recombinant ETS1 binds
strongly to the 2G promoter and weakly to the 1G
promoter and that this binding is dependent on coop-
eration with an adjacent AP1 site at -1602 [16]. Their
study along with others have revealed that several
members of the AP1 family, including c-JUN, Fra and
Fos, are involved in the heterodimmer complexes
bound at this cooperative AP1 site [16,35,36]. While
the limited ChIP analysis we have performed clearly
indicated that GATA3, Fos, Ets1 and Ets2 do indeed
bind to this region of the MMP1 promoter, further
studies using larger numbers of individuals will be
required to identify differential binding between geno-
types or cell culture conditions.
Conclusion
Identifying the functional importance of the millions of
human SNPs is becoming a major challenge. Simulta-
neously, the amount of available RNA transcriptome data
is rapidly growing, driving scientists to devise new meth-
ods to extract the most biologically and clinically useful
information from RNA abundance profiles. Therefore, a
strategy that identifies functionally important SNPs by
virtue of the bimodal abundance across the human popu-
lation of the associated mRNAs is potentially very useful.
Here, we discuss a simple method based on hierarchical
clustering to identify bimodally expressed transcripts,
which may be used with either microarray or RNAseq
data. This method complements more statistically com-
plex approaches and is suitable for use by laboratory
scientists with only basic statistical training, who are in a
good position to immediately follow up their results
experimentally. This strategy identified bimodal endothe-
lial cell expression of several transcripts including
MMP1, which appears to be biologically significant with
implications for inflammatory disease and for
Figure 7 Immunoblot illustrating inflammatory signalling responses in 3 isolates with low and high basal expression of MMP-1
(labelled isolates 1, 2, 3 and 4, 5, 6 respectively). Low = low basal expressers and High = high basal expressers. Time in hours for each
group of low and high basal expressers is given at the top of the figure. (a) IBa signalling over 3.5 hours after the addition of an inflammatory
mediator cocktail containing 10 ng/ml each of TNF-a, Il-1b and Il-8. (b) Phosphorylated IBa signalling over the time course. (c) ICAM signalling
over the time course. Both the high expressers and low expressers show similar levels of IBa, phospho- IBa and ICAM over the time course.
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and polymorphic promoter elements.
Methods
Cell culture and IM treatment
Umbilical cords were collected after written informed
consent and the study was approved by the Cambridge
Research Ethics Committee. The population sampled for
this study were of unknown demography, with no infor-
mation obtained during donor collection relating to
parental age, ethnicity or familial history of disease.
HUVECs were isolated by collagenase digestion, as pre-
viously described [37]. Cells were cultured in fully sup-
plemented media without antibiotics (basal EBM-2 with
a propriety mix of heparin, hydrocortisone, vascular
endothelial growth factor, epidermal growth factor,
fibroblast growth factor, 2% foetal calf serum (FCS,
Lonza, Cambridge, UK), at 37°C/5% CO2 until passage
4. To carry out inflammatory mediator treatment
for microarray gene expression profiling, passage 4
HUVECs were treated with a cocktail of 10 ng/ml TNF-
a, IL-1b and IL-8 for 24 hours prior to RNA extraction.
RNA processing and microarray preparation and data
processing
RNA was extracted using TRIzol
® reagent (Invitrogen,
London UK). RNA quality was assessed using the Agi-
lent 2100 bioanalyser. Biotin labelled cRNA was gener-
ated and hybridised on the CodeLink Human Uniset
20K microarrays following the manufacturer’si n s t r u c -
tions (Applied Microarrays, formally supplied by GE
Healthcare). CodeLink microarray data was pre-
processed to assess array quality using the CodeLink
Expression analysis software v4.0. To enable comparable
analysis between arrays, normalisation was carried out
using the cyclic Loess method [38,39]. The microarray
data has been deposited in NCBI’sG e n eE x p r e s s i o n
Omnibus (GEO) [40] and can be accessed through GEO
series accession number GSE23070.
Bimodal analysis of microarray expression data
To identify bimodally expressed RNA transcripts, RNA
w a sp r e p a r e df r o mp a s s a g e4H U V E C si s o l a t e df r o m1 5
different individuals and analysed using CodeLink
Human Uniset 20K microarrays (the untreated (UT)
Figure 8 Fold enrichment of transcription factor binding to the region of the -1607 MMP1 promoter polymorphism.( a )F o l d
enrichment of c-Fos, ETS1 and ETS2 binding at the region of the -1607 promoter polymorphism relative to a region 5600 bases upstream of the
promoter polymorphism. (b) Complete replication of experiment in 5a using cells from different 1G and 2G individuals. (c) Fold enrichment of
GATA3 binding at the region of the -1607 promoter polymorphism relative to a region 5600 bases upstream of the promoter polymorphism.
(d) Replication of experiment 5c. Input control refers to enrichment in the absence of any precipitating antibody.
Affara et al. BMC Genomics 2011, 12:43
http://www.biomedcentral.com/1471-2164/12/43
Page 10 of 13data set). In addition, passage 4 HUVECs isolated from
9 different individuals were each treated with 10 ng/ml
of each of TNF-a,I L - 1 b, Il-8, and analysed using
microarrays as described above (the inflammatory
mediator treated (IM) data set). Unsupervised agglom-
erative clustering was then applied separately to the
UT and IM data sets to enrich for multimodality,
using R bioinformatic software (freely available at
http://cran.r-project.org/). For each transcript, our
algorithm recorded the “height” (Euclidian distance)
between the clusters. The height values at either end
of the cluster dendrogram were discarded to remove
cases where the clustering identified a single outlying
individual, and the largest remaining height value was
used as an indicator of bimodality/multimodality. For
those RNAs with signal intensities that were similar
across the set of individuals, the height between clus-
ters is likely to be small. However, where there were
two or more distinct clusters of expression values
among the set of individuals, the height between clus-
ters is likely to be large. In addition, parametric boot-
strapping was carried out during the clustering process
to identify the likelihood of identifying the given height
value for each gene based on chance alone, as sum-
marised in Figure 1 and in the comments within the R
script in Additional File 1. To be strictly statistically
correct, the permutation p-values should be adjusted
for multiple testing. For example the Benjamini &
Hochberg procedure could be used to control the false
d i s c o v e r yr a t eb ya p p l y i n gt h em t . r a w p 2 a d j pf u n c t i o n
of the ‘multtest’ R package to the p-values produced
from the bootstrap procedure described here. However,
this is not included in the current iteration of our
method, since it does not alter the ranking of the per-
mutation p-values assigned to each RNA, and it
appears to be overly stringent since it masks both of
the bimodally-expressed RNAs that were experimen-
tally confirmed in our study. Nevertheless, if larger
data sets are analysed, from which the degree of bimo-
dal expression and population distribution parameters
for each RNA can be estimated more precisely, it may
be worth experimenting with various multiple testing
control procedures.
Inflammatory mediator time course and immunoblotting
For the inflammatory mediator time course, passage 4
HUVECs were treated with a cocktail of 10 ng/ml of
each of TNF-a,I L - 1 b,I L - 8f o ru pt o3 . 5h o u r s .W h o l e
cell lysates were harvested by scraping in 1X RIPA lysis
buffer (Millipore, Watford, UK) with protease inhibitors
(Roche, Welwyn Garden City, UK), at time points 0, 0.5,
1.5 and 3.5 hours. Proteins were separated on 12% Tris-
glycine SDS-page gels (Invitrogen) and transferred to 0.2
μm nitrocellulose membranes (Invitrogen). All
membranes were blocked with 5% skimmed milk in
Tris-buffered saline/0.01% Tween
®20 at room tempera-
ture. Blots were probed with antibodies against ETS1
(sc-350) and ETS2 (sc-351) (both from Santa Cruz Bio-
technology) and b-actin (Ambion).
MMP1 activity assay
Total active MMP1 protein abundance was measured
using the Fluorokine Human Active MMP1 Fluorescent
Assay (R&D Systems). Supernatants were collected from
the cell culture of 20 different passage 4 HUVEC iso-
lates, treated with and without an inflammatory media-
t o rc o c k t a i lo f1 0n g / m lT N F - a,I L - 1 b,I L - 8f o r2 4 h r s .
P-Aminophenylmercuric Acetate (APMA) was added to
all samples to activate any inactive MMP1. Measure-
ment of MMP1 activity was carried out according to the
manufacturer’s instructions.
Sequencing of the MMP1 promoter polymorphism
To characterise the -1607 MMP1 promoter polymorph-
ism, DNA was extracted from HUVEC cell pellets using
t h eD N e a s yb l o o da n dt i s s u ek i t( Q i a g e n ,W e s tS u s s e x ,
UK), following the manufacturer’s instructions. Genomic
DNA (50 ng) was amplified with the following primers:
5’-AACCTATTAACTCACCCTTGT-3’ 5’-CCTCCATT-
CAAAAGATCTTATTATTTAGCATCTCCT-3’ [34].
The cycling conditions were as follows: pre-incubation
at 94°C for 5 minutes, followed by 35 cycles at 94°C for
30 seconds, 56°C for 30 seconds and 72°C for 1 minute,
followed by a final extension at 72°C for 10 minutes.
PCR products were diluted 1 in 10 in nuclease free
water and directly sequenced using the forward primer
at GeneService (Cambridge Science Park, Milton, UK).
Amplification of the MMP1 promoter region spanning
the -930 and -519 polymorphisms was achieved using
the same conditions described above using the following
primers: 5’-TTCCAGCCTTTTCATCATCC-3’ and
5’-CGGCACCTGTACTGACTGAA-3’.A g a i nt h ef o r -
ward primer was used for sequencing.
Quantitative PCR
cDNA was made from 1 μg of total RNA using the Quan-
titect reverse transcription kit (Qiagen), following the
manufacturers protocol. Quantitative PCR was carried
out using the the ABI 7700 sequence analyser (Applied
Biosystems, Calafornia, USA). Reactions were carried out
using the Applied Biosystems universal master mix
according to the manufacturers instructions. The Taq-
man probe primers used were: MMP1 (Hs00233958_m1),
DDX3Y (Hs00190539_m1), ETS1 (Hs00901425_m1),
ETS2 (Hs00232009_m1), GATA3 (Hs00231122_m1),
SLC2A11 (Hs00368843_m1), DERP6 (Hs00209768_m1)
and internal control 18S (Hs99999901_s1), all from
Applied Biosystems.
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Page 11 of 13Chromatin immunoprecipitation
Passage 4 HUVECs were either treated with vehicle or
an inflammatory cocktail of 10 ng/ml TNF-a,I L - 1 b,I L -
8 for 24 hours. Chromatin was cross-linked by the addi-
tion of formaldehyde to a final concentration of 1% for
10 minutes at 37°C. Cells were washed in ice cold phos-
phate-buffered saline containing 125 mM glycine, 1 mg/
ml Pefabloc, 1 μg/ml aprotinin and 1 μg/ml pepstatin A.
Chromatin was sonicated and immunoprecipitated using
specific antibodies, as described in the ChIP protocol
from Upstate Inc. (Charlottesville, VA). The following
antibodies were used: ETS1 (sc-350), ETS2 (sc-351), c-
Fos (sc-52) and GATA3 (sc-268). All antibodies were
from Santa Cruz Biotechnologies. To quantify enrich-
ment of binding, quantitative PCR was carried out on
the immunoprecipitated DNA using SYBR Green on the
iCycler (Roche). 25 μl reactions with 1 X SensiMixPlus
SYBR and fluorescein (Quantace) were carried out
according to the manufacturer’s instructions. Primers
around the MMP1 polymorphism were 5’-
TCTTTGTCTGTGCTGGAGTA-3’ and 5’-
CAATTTCCTCATCTAAGTGGCATA-3’.T h ep r i m e r s
for the region 5600 bases upstream of the promoter
were 5’-TGCTTATGTTAGCTGACCAGAC-3’ and
5’-AGTATGCGTTGCCTTGTCCT-3’.
Additional material
Additional file 1: R-script: Source code to identify and visualise
bimodally expressed transcripts from a microarray expression dataset.
Additional file 2: Clustering results: Clustering results for both the un-
treated (UT) and IM-treated (IM) HUVEC data set are shown for 10531
RNA transcripts. “OGS” is the official human gene symbol. “max_height”
denotes the greatest distance (maximum cluster branch height) between
the any two clusters of individuals, and is used a surrogate marker for
the degree of bimodal expression. “p_max_height” denotes, for this
transcript, the frequency with which this maximum cluster branch height
is exceeded in clustering of 1,000 simulated data sets generated by
aprametric bootstrapping (an estimate of the probability of each
transcripts appearing to be bimodally expressed due to chance alone).
Additional file 3: Table of 21 short listed RNA transcripts: Table of
features for each of the 21 RNA transcripts to help determine selection
Additional file 4: R-script: To plot histograms.
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